Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Malignant Neoplasm
71%
Gastrointestinal Stromal Tumor
69%
Metastatic Colorectal Cancer
67%
Progression Free Survival
60%
Imatinib
60%
Neoplasm
57%
Colorectal Cancer
55%
Chemotherapy
50%
Fluorouracil
47%
Clinical Trial
43%
Phase II Trials
42%
Cetuximab
35%
Disease
35%
Folinic Acid
31%
Bevacizumab
29%
Colon Cancer
25%
Irinotecan
22%
Leukemia
22%
Adverse Event
22%
Recurrent Disease
20%
Cisplatin
19%
Gemcitabine
18%
Disease Free Survival
18%
Paclitaxel
18%
Adenocarcinoma
17%
Randomized Clinical Trial
16%
Pancreas Cancer
16%
Esophagus Cancer
15%
Nivolumab
14%
Ipilimumab
14%
Placebo
13%
Oxaliplatin
13%
Epidermal Growth Factor Receptor
13%
Non Small Cell Lung Cancer
13%
Diarrhea
12%
Trimetrexate
11%
Celecoxib
11%
Cytotoxic T Lymphocyte Antigen 4
11%
Protein Tyrosine Kinase Inhibitor
9%
Cohort Study
9%
Chemoradiation Therapy
9%
Lung Cancer
9%
Erlotinib
9%
Recurrence Free Survival
9%
Stomach Cancer
8%
Biological Marker
8%
Neutropenia
8%
Bile Duct Carcinoma
8%
Sorafenib
8%
Medicine and Dentistry
Malignant Neoplasm
63%
Overall Survival
61%
Gastrointestinal Stromal Tumor
57%
Oncology
53%
Progression Free Survival
45%
Imatinib
38%
Clinical Trial
37%
Disease
35%
Neoplasm
35%
Colorectal Cancer
34%
Phase II Trials
31%
Metastatic Colorectal Cancer
29%
Rare Tumor
28%
Surgery
23%
Radiation Therapy
21%
Hazard Ratio
21%
Fluorouracil
21%
Cetuximab
20%
Arm
18%
Nivolumab
17%
Ipilimumab
17%
Targeted Therapy
17%
Adverse Event
17%
Cisplatin
16%
Gemcitabine
16%
Cholangiocarcinoma
13%
Chemoradiotherapy
13%
Recurrent Disease
13%
Cancer
13%
Folinic Acid
13%
Esophageal Cancer
12%
Metastatic Carcinoma
12%
Colon Cancer
12%
Leukemia
12%
Adenocarcinoma
11%
Trimetrexate
11%
Non Small Cell Lung Cancer
11%
Placebo
10%
Lung Cancer
10%
Disease Free Survival
9%
Adjuvant Therapy
9%
CTLA-4
9%
Gallbladder Cancer
8%
Irinotecan
8%
Etoposide
8%
Capecitabine
8%
Esophageal Adenocarcinoma
8%
Gallbladder Carcinoma
8%
Recurrence Free Survival
8%
Survival Rate
8%
Keyphrases
Gastrointestinal Stromal Tumor
43%
Overall Survival
35%
Phase II Trial
34%
Phase II Study
30%
Imatinib
29%
Progression-free Survival
28%
5-fluorouracil (5-FU)
27%
Southwest Oncology Group
23%
Leucovorin
22%
Metastatic Colorectal Cancer (mCRC)
22%
Colorectal Cancer
22%
Partial Response
21%
Rare Tumors
21%
Metastatic Gastrointestinal Stromal Tumor
20%
PD-1 Blockade
17%
Chemotherapy
16%
Advanced Colorectal Cancer
16%
Nivolumab
16%
Ipilimumab
16%
Confidence Interval
16%
Basket Trial
16%
Imatinib Mesylate
15%
Gemcitabine
14%
Advanced Gastrointestinal Stromal Tumor
14%
Hazard Ratio
14%
Advanced or Metastatic
13%
Stable Disease
13%
Response Rate
13%
Tumor
12%
Previously Untreated
11%
Complete Response
11%
Group Studies
11%
Celecoxib
11%
Irinotecan
11%
Targeted Therapy
11%
Median Overall Survival
11%
Gallbladder Cancer
10%
Cisplatin
10%
Cetuximab
10%
Radiotherapy
10%
Epidermal Growth Factor Receptor
9%
Randomized Clinical Trial
9%
Median Survival
9%
Paclitaxel
9%
Disease-free Survival
9%
Anti-CTLA-4
9%
Bevacizumab
9%
Overall Response Rate
9%
Erlotinib
9%
Diarrhea
9%